Investor Update: Roche Chairman Franz B. Humer announces that he will not stand for re-election in 2014
Basel, 5 March 2013
Roche to inform about plans for succession in autumn 2013
Franz B. Humer, Chairman of the Board of Directors of the Roche Group, announced at today's Annual General Meeting that he will not stand for re-election to the Board in 2014. Roche will nominate a successor for the chairmanship in autumn 2013. The Roche Board has decided that Franz Humer's successor will also serve as non-executive Chairman, thus maintaining the established separation of the offices of Chairman and Chief Executive Officer.
Roche Chairman Franz B. Humer: "Roche is in excellent shape and well positioned to meet future challenges. This is a good time to hand over to a successor. I am looking forward to the next 12 months, and I intend to perform my duties as Chairman with enthusiasm and drive."
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company, with truly differentiated medicines in oncology, infectious diseases, inflammation, metabolism and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2012 Roche had over 82,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 45.5 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
- Address by Franz B. Humer: http://www.roche.com/agm13_fbh_e.pdf